The compliance notice removes a key overhang for PDSB, which had a $64M market cap and 89% analyst bullish consensus. Monitor the stock's ability to sustain above $1.00; any subsequent dip below that threshold could trigger a new 180-day cure period. No financial data or guidance was provided in this filing.
PDSB drugs
PDSB drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 2 $1.16entry
- T+1 · 6mo ago −6.90%α −6.20% · $1.08
- T+5 · 5mo ago −11.21%α −8.24% · $1.03
- T+20 · 5mo ago −24.66%α −23.09% · $0.8740
- T+60 · 3mo ago −80.76%α −81.88% · $0.2232
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PDS Biotechnology Corp received a Nasdaq notice on June 2, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement, closing the deficiency matter first disclosed on February 25, 2026. This removes the immediate delisting risk from Nasdaq, a positive administrative outcome for the $64M market cap clinical-stage biotech.
Key Facts
- On February 25, 2026, PDSB received a Nasdaq deficiency letter for trading below $1.00 for 30 consecutive business days.
- On June 2, 2026, Nasdaq notified PDSB that it has regained compliance with the minimum bid price requirement and closed the matter.
- The company's common stock continues to trade on The Nasdaq Capital Market under the symbol PDSB.
Financial Impact
No direct financial figures provided; the filing resolves a delisting risk that could have forced a transfer to OTC markets, preserving Nasdaq listing and associated liquidity/premium.
Risk Factors
- Stock could again fall below $1.00, triggering a new deficiency process.
- No operational or financial catalysts were disclosed; the compliance notice does not change the company's clinical-stage risk profile.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-023698 |
| Document: 0001140361-26-023698-index-headers.html | 0001140361-26-023698 |
| Document: 0001140361-26-023698.txt | 0001140361-26-023698 |
Track record
28 reports on PDSB
7 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 13 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers